<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
    <link rel="stylesheet" href="../css/uswds.min.css">
    <link rel="stylesheet" href="../css/style.css">
    <link rel="stylesheet" href="css/uswds.min.css">
    <link rel="stylesheet" href="css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title42.html">
                                    Title 42
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/42CFR423.html">Part 423
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 423.132  Public disclosure of pharmaceutical prices for
                            </h3>
                            <p class="depth1"><em>(a)</em> General requirements. Except as provided under paragraph (c) of this section, a Part D sponsor must require a pharmacy that dispenses a covered Part D drug to inform an enrollee of any differential between the price of that drug and the price of the lowest priced generic version of that covered Part D drug that is therapeutically equivalent and bioequivalent and available at that pharmacy, unless the particular covered Part D drug being purchased is the lowest-priced therapeutically equivalent and bioequivalent version of that drug available at that pharmacy.</p><p class="depth1"><em>(b)</em> Timing of notice. Subject to paragraph (d) of this section, the information under paragraph (a) of this section must be provided after the drug is dispensed at the point of sale or, in the case of dispensing by mail order, at the time of delivery of the drug.</p><p class="depth1"><em>(c)</em> Waiver of public disclosure requirement. CMS waives the requirement under paragraph (a) of this section in any of the following cases:</p><p class="depth2"><em>(1)</em> An MA private fee-for-service plan described in Sec. 422.4 of this chapter that--</p><p class="depth3"><em>(i)</em> Offers qualified prescription drug coverage and provides plan enrollees with access to covered Part D drugs dispensed at all pharmacies, without regard to whether they are contracted network pharmacies; and</p><p class="depth3"><em>(ii)</em> Does not charge additional cost-sharing for access to covered Part D drugs dispensed at out-of-network pharmacies.</p><p class="depth2"><em>(2)</em> An out-of-network pharmacy.</p><p class="depth2"><em>(3)</em> An I/T/U network pharmacy.</p><p class="depth2"><em>(4)</em> A network pharmacy that is located in any of the U.S. territories.</p><p class="depth2"><em>(5)</em> A long-term care network pharmacy.</p><p class="depth2"><em>(6)</em> Other circumstances where CMS deems compliance with the requirements of paragraph (a) of this section to be impossible or impracticable.</p><p class="depth1"><em>(d)</em> Modification of timing requirement. CMS modifies the requirement under paragraph (b) of this section under circumstances where CMS deems compliance with this requirement to be impossible or impracticable.
[70 FR 4525, Jan. 28, 2005, as amended at 75 FR 19818, Apr. 15, 2010]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>. Code available <a href="#">on Github.</a></h5>
      </div>
    </div>
  </footer>
  </body>
</html>
